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We read with some concern the recent article in Genetics in Medicine reporting a high lifetime risk 
of breast cancer in pathogenic variant (PV) carriers for PMS2 and MSH6 [1]. Although the reported 
odds ratios for breast cancer were given as: MSH6 (2.11; 95%CI=1.56–2.86) and PMS2 (2.92; 95% 
CI=2.17–3.92) the cumulative risks to age 60 were given as 31.1% (95%CI, 21.9–40.7) and 37.7% 
(95% CI, 27.5–47.8) respectively. These are equivalent to UK NICE defined high-lifetime risks. These 
two analyses are inaccurate given that the risk of breast cancer to the age of 60 years in the UK and 
USA is 5-6%.  Therefore, if the risks from incidence ratios and Kaplan-Meier were equivalent, the 
odds ratios would be over 6-fold for PMS2 and >5 fold for MSH6. 
The most meaningful unbiased risks are likely to come from prospective analysis.  The cumulative 
risk to age 70 years in 124 PMS2 PV carriers was shown to be only 8.6% to age 70 years in the largest 
such analysis undertaken thus far [2]. A single case between70-75 years gave a distorted non-
significant increased risk. For MSH6 the cumulative risk to age 75 years was 13.3% (95%CI=2.2-24.4) 
Odds ratio 1.4 (95% CI=0.2-2.6). As such the upper confidence interval at age 75 years for MSH6 
rules out the cumulative risks provided by the GeneDx study [1]. 
The huge discrepancy observed may be attributed to a number of issues including: (i) the lack of 
adjustment of the clear ascertainment bias in contrast with the majority of published reports of 
cumulative risk of breast cancer in patients with tumour suppressor gene variants; (ii) the absence of 
information on the proportion of women who were tested who had a breast cancer diagnosis.  An 
earlier report from this group reported 5209/9276 (56.2%) of all referred samples had breast cancer 
[3]. If the proportion remains constant a huge bias is present that precludes any comparison of 
incidence ratios with the general population; (iii) the authors ‘compound the felony’ with the 
inappropriate use of Kaplan-Meier analyses for cumulative risks.  Despite the fact the authors report 
an odds ratio of below one for MLH1, they then report a 15.5% (95%CI=5.5–30.2) risk of breast 
cancer by age 60 years. This is equivalent to a 3-fold excess risk. It is therefore highly likely that if the 
authors had carried out incidence ratios for those individuals testing negative for mis-match repair 
(MMR) and other PV, they would have demonstrated an increased risk with a cumulative risk to age 
60 years of over 25%; and (iv) The authors have not reported whether the variants segregated with 
disease which would at least have provided some supportive data. Whilst the authors state that ‘the 
risks of other cancers, including breast are less clearly delineated’ this ignores most of the negative 
evidence available [2,4].  
A more appropriate use of panel data to agnostically assess cancer risks would be to carry out a case 
control analysis. The largest analysis published thus far from Ambry Genetics (n= 65,057 women) [5] 
found an odds ratio below one for PMS2 although a potential risk was seen for MSH6 with an odds 
ratio of 1.93; (95%CI=1.16-3.27). Given the likely ratio of around 50% for those tested with breast 
cancer to those without, a form of internal case control for PMS2 could be carried out within the 
available results. Interestingly for PMS2 this was close to a 1:1 ratio with 35.5% having breast cancer 
and 34.7% without breast or another cancer. If one took the 0.13% prevalence of PMS2 PV in the 
Ambry report as a control, then assuming the frequency of breast cancer cases was similar to the 
56% in GeneDx first report, the reported incidence would be 44/28078 or 0.16% providing an odds 
ratio of only 1.2. As we were not provided with the proportion of breast cancers we cannot be 
certain of this figure but it is unlikely to have risen above an odds ratio of 2-fold. Even these case 
control series are limited by their use of control data.  
Another important issue is that three of the panel tests provided by GeneDx exclude a real 
assessment of breast cancer genes and most of the MSH2 and MLH1 carriers (52% and 64%) were 
detected using the colorectal 16 gene panel or high-risk Lynch/colorectal 7 gene panel or 
endometrial 12 gene panel. This compared to only 18% of PMS2 and 35% of MSH6 (p<0.0001 for 
difference between gene duos). Ironically it may be because PMS2 gives such lower overall risks of 
cancer that it has come out giving the highest risks of breast cancer in the GeneDx analysis paper [1]. 
It is crucially important that those discussing breast cancer risks with women with pathogenic PMS2 
and MSH6 variants do not base their advice or management on the reported findings rather on the 
overall evidence available, in particular that coming from prospective observations in large numbers 
of cases.  
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